Catalent will shell out $230 million to expand the viral vector manufacturing operation at its Harmans, Maryland, gene therapy campus.
The latest project by the New Jersey-based CDMO will add three more commercial-scale viral vector suites as well as expanded storage space, ultralow temperature freezers and water-for-injection infrastructure, the company said Tuesday.
The latest investment by Catalent comes a year after the company piled $130 million into the site in the race to manufacture COVID vaccines.
